Skip to main content
Erschienen in: Medical Microbiology and Immunology 3/2008

01.09.2008 | Rapid Communication

Seroprevalence of varicella zoster virus infection in child and adult population of Catalonia (Spain)

verfasst von: Lluís Salleras, Àngela Domínguez, Pere Plans, Josep Costa, Neus Cardeñosa, Núria Torner, Antoni Plasència

Erschienen in: Medical Microbiology and Immunology | Ausgabe 3/2008

Einloggen, um Zugang zu erhalten

Abstract

The aim of this study was to determine the prevalence of varicella IgG antibodies in the population of Catalonia, and the variables associated. The study was carried out in 2002 in a representative sample of juvenile (5–14 years) and adult population (≥15 years) of Catalonia (Spain). The global prevalence determined by ELISA test was 95.5% (95% CI 94.7–96.3). The prevalence increased with age, from 82% (95% CI 77.0–87.0) in the 5–9 years age up to 99.4% (95% CI 98.2–100) in >64 years of age. No statistically significant differences in the seroprevalence according to the sociodemographic variables were observed. The current strategy of vaccinating preadolescents at 12 years of age who have not suffered the disease will require more than 30 years to cover the current gap immunity in adolescents and young adults. Vaccination with two doses of vaccine for all adolescents and adults ≤ 50 years who report not having suffered the disease during childhood should be considered.
Literatur
2.
Zurück zum Zitat Salleras L, Pujals JM, Salleras M (2003) Vacuna antivarizela-zoster. In: Salleras L (eds) Vacunaciones preventivas, 2nd edn. Masson, Barcelona, pp 311–330 Salleras L, Pujals JM, Salleras M (2003) Vacuna antivarizela-zoster. In: Salleras L (eds) Vacunaciones preventivas, 2nd edn. Masson, Barcelona, pp 311–330
3.
Zurück zum Zitat Sauerbrei A, Wutzler P (2007) Herpes simplex and varicella-zoster virus infections during pregnancy: current concepts of prevention, diagnosis and therapy. Part 2: Varicella-zoster virus infections. Med Microbiol Immunol 196:95–102PubMedCrossRef Sauerbrei A, Wutzler P (2007) Herpes simplex and varicella-zoster virus infections during pregnancy: current concepts of prevention, diagnosis and therapy. Part 2: Varicella-zoster virus infections. Med Microbiol Immunol 196:95–102PubMedCrossRef
4.
Zurück zum Zitat Hambleton S, Gershon AA (2005) Preventing varicella-zoster disease. Clinical Microbiol Rev 18:70–80CrossRef Hambleton S, Gershon AA (2005) Preventing varicella-zoster disease. Clinical Microbiol Rev 18:70–80CrossRef
5.
Zurück zum Zitat Armitage P, Berry G, Matthews JNS (2002) Statistical methods in medical research, 4th edn. Blackwell Science Limited, London Armitage P, Berry G, Matthews JNS (2002) Statistical methods in medical research, 4th edn. Blackwell Science Limited, London
6.
Zurück zum Zitat Office of Population Census and Surveys (1980) Classification of occupations. Office of Population Census, London Office of Population Census and Surveys (1980) Classification of occupations. Office of Population Census, London
7.
Zurück zum Zitat Demmeler GJ, Steinberg SP, Blum G, Gershon AA (1988) A rapid enzyme-linked immunosorbent assay for detecting antibodies to varicella-zoster virus. J Infect Dis 157:211–212 Demmeler GJ, Steinberg SP, Blum G, Gershon AA (1988) A rapid enzyme-linked immunosorbent assay for detecting antibodies to varicella-zoster virus. J Infect Dis 157:211–212
8.
Zurück zum Zitat Salleras L, Domínguez A, Vidal J, Plans P, Salleras M, Taberner JL (2001) Seroepidemiology of varicella-zoster virus infection in Catalonia (Spain). Rationale for universal vaccination programmes. Vaccine 19:183–188CrossRef Salleras L, Domínguez A, Vidal J, Plans P, Salleras M, Taberner JL (2001) Seroepidemiology of varicella-zoster virus infection in Catalonia (Spain). Rationale for universal vaccination programmes. Vaccine 19:183–188CrossRef
9.
Zurück zum Zitat Wharton M (1996) The epidemiology of varicella-zoster virus infection. Infect Dis Clin North Am 10:571–581PubMedCrossRef Wharton M (1996) The epidemiology of varicella-zoster virus infection. Infect Dis Clin North Am 10:571–581PubMedCrossRef
10.
Zurück zum Zitat Ooi PL, Goh KT, Doraisingham S, Ling AE (1992) Prevalence of varicella-zoster virus infection in Singapore. Southeast Asian J Trop Med Public Health 23:22–25PubMed Ooi PL, Goh KT, Doraisingham S, Ling AE (1992) Prevalence of varicella-zoster virus infection in Singapore. Southeast Asian J Trop Med Public Health 23:22–25PubMed
11.
Zurück zum Zitat Pachón I, Amela C, de Ory F, León P, Alonso M (1998) Encuesta nacional de seroprevalencia de enfermedades inmunoprevenibles. Año 1996. Bol Epidemiol Semanal 6:93–104 Pachón I, Amela C, de Ory F, León P, Alonso M (1998) Encuesta nacional de seroprevalencia de enfermedades inmunoprevenibles. Año 1996. Bol Epidemiol Semanal 6:93–104
12.
Zurück zum Zitat Gil A, González A, Dal-Ré R, Ortega P, Domínguez V (1998) Prevalence of antibodies against varicella zoster, Herpes simples (Types 1 and 2), hepatitis B and hepatitis A virases among Spanish adolescents. J Infect 36:53–6PubMedCrossRef Gil A, González A, Dal-Ré R, Ortega P, Domínguez V (1998) Prevalence of antibodies against varicella zoster, Herpes simples (Types 1 and 2), hepatitis B and hepatitis A virases among Spanish adolescents. J Infect 36:53–6PubMedCrossRef
13.
Zurück zum Zitat Díez-Domingo J, Gil A, San-Martín M et al (2005) Seroprevalence of varicella among children and adolescents in Valencia, Spain: reliability of the parent’s reported history and the medical file for identification of potential candidates for vaccination. Hum Vaccin 1:204–206PubMed Díez-Domingo J, Gil A, San-Martín M et al (2005) Seroprevalence of varicella among children and adolescents in Valencia, Spain: reliability of the parent’s reported history and the medical file for identification of potential candidates for vaccination. Hum Vaccin 1:204–206PubMed
14.
Zurück zum Zitat Aebi C, Fischer K, Gorgievski M, Matter L, Muhlemann K (2001) Age-specific seroprevalence to varicella-zoster virus: study in Swiss children and analysis of European data. Vaccine 19:3097–3103PubMedCrossRef Aebi C, Fischer K, Gorgievski M, Matter L, Muhlemann K (2001) Age-specific seroprevalence to varicella-zoster virus: study in Swiss children and analysis of European data. Vaccine 19:3097–3103PubMedCrossRef
15.
Zurück zum Zitat Svahn A, Bergren J, Parke A, Storsaeter J, Thorstensson R, Linde A (2006) Changes in seroprevalence to four herpesvirus over 30 years in Swedish children aged 9–12 years. J Clin Virol 37:118–123PubMedCrossRef Svahn A, Bergren J, Parke A, Storsaeter J, Thorstensson R, Linde A (2006) Changes in seroprevalence to four herpesvirus over 30 years in Swedish children aged 9–12 years. J Clin Virol 37:118–123PubMedCrossRef
16.
Zurück zum Zitat Koskiniemi M, Lappalainen M, Schmid DS, Rubtcova E, Loparev VN (2007) Genotypic analysis of varicella-zoster virus and its seroprevalence in Finland. Clin Vaccine Immunol 14:1057–1061PubMedCrossRef Koskiniemi M, Lappalainen M, Schmid DS, Rubtcova E, Loparev VN (2007) Genotypic analysis of varicella-zoster virus and its seroprevalence in Finland. Clin Vaccine Immunol 14:1057–1061PubMedCrossRef
17.
Zurück zum Zitat Wutzler P, Färber I, Wagenpfeil S, Bisanz H, Tischer A (2001) Seroprevalence of varicella-zoster virus in the German population. Vaccine 20:1214124PubMedCrossRef Wutzler P, Färber I, Wagenpfeil S, Bisanz H, Tischer A (2001) Seroprevalence of varicella-zoster virus in the German population. Vaccine 20:1214124PubMedCrossRef
18.
Zurück zum Zitat Thiry N, Beutels P, Shkedy Z, Vranckx R, Vandermeulen C, Wielen MV et al (2002) The seroepidemiology of primary varicella-zoster virus infection in Flanders (Belgium). Eur J Pediatr 161:588–593PubMedCrossRef Thiry N, Beutels P, Shkedy Z, Vranckx R, Vandermeulen C, Wielen MV et al (2002) The seroepidemiology of primary varicella-zoster virus infection in Flanders (Belgium). Eur J Pediatr 161:588–593PubMedCrossRef
19.
Zurück zum Zitat Mossong J, Putz L, Schneider F (2004) Seroprevalence and force of infection of varicella-zoster virus in Luxembourg. Epidemiol Infect 132:1121PubMedCrossRef Mossong J, Putz L, Schneider F (2004) Seroprevalence and force of infection of varicella-zoster virus in Luxembourg. Epidemiol Infect 132:1121PubMedCrossRef
20.
Zurück zum Zitat de Melker H, Berbers G, Hahne S et al (2006) The epidemiology of varicella and herpes zoster in The Netherlands: implications for varicella zoster virus vaccination. Vaccine 24:3946–3952PubMedCrossRef de Melker H, Berbers G, Hahne S et al (2006) The epidemiology of varicella and herpes zoster in The Netherlands: implications for varicella zoster virus vaccination. Vaccine 24:3946–3952PubMedCrossRef
21.
Zurück zum Zitat Khoshnood B, Debruyne M, Lançon F et al (2006) Seroprevalence of varicella in the French population. Pediatr Infect Dis J 25:41–44PubMedCrossRef Khoshnood B, Debruyne M, Lançon F et al (2006) Seroprevalence of varicella in the French population. Pediatr Infect Dis J 25:41–44PubMedCrossRef
22.
Zurück zum Zitat Gabuti G, Penna C, Rossi MA et al (2001) The seroepidemiology of varicella in Italy. Epidemiol Infect 126:433–440CrossRef Gabuti G, Penna C, Rossi MA et al (2001) The seroepidemiology of varicella in Italy. Epidemiol Infect 126:433–440CrossRef
23.
Zurück zum Zitat Gürgöze MK, Yılmaz E, Gödekmerdan A, Akça Z, Doğan Y, Akarsu S, Denizmen Aygün A (2006) Seroprevalence of mumps, varicella and rubella antibodies in children 1–16 years of age in eastern Turkey. Turk J Pediatr 48:185–188PubMed Gürgöze MK, Yılmaz E, Gödekmerdan A, Akça Z, Doğan Y, Akarsu S, Denizmen Aygün A (2006) Seroprevalence of mumps, varicella and rubella antibodies in children 1–16 years of age in eastern Turkey. Turk J Pediatr 48:185–188PubMed
24.
Zurück zum Zitat Kurugol Z, Koturoglu G, Aksit S, Ozacar T (2007) Varicella seroprevalence in Turkish population in Cyprus. Acta Paediatr 96:861–863PubMedCrossRef Kurugol Z, Koturoglu G, Aksit S, Ozacar T (2007) Varicella seroprevalence in Turkish population in Cyprus. Acta Paediatr 96:861–863PubMedCrossRef
25.
Zurück zum Zitat Breuer J (2004) Varicella zoster virus. In: Zuckerman AJ, Banatvala JE, Pattison JR, Griffiths PD, Schoub BD (eds) Principles and practice of clinical virology, 5th edn. Wiley, Chichester, pp 53–83CrossRef Breuer J (2004) Varicella zoster virus. In: Zuckerman AJ, Banatvala JE, Pattison JR, Griffiths PD, Schoub BD (eds) Principles and practice of clinical virology, 5th edn. Wiley, Chichester, pp 53–83CrossRef
26.
Zurück zum Zitat Cohen DI, Davidovici BB, Smetana Z, Balicer RD, Klement E, Mendelson E, Green MS (2006) Seroepidemiology of varicella zoster in Israel prior to large-scale use of varicella vaccines. Infection 34:208–213PubMedCrossRef Cohen DI, Davidovici BB, Smetana Z, Balicer RD, Klement E, Mendelson E, Green MS (2006) Seroepidemiology of varicella zoster in Israel prior to large-scale use of varicella vaccines. Infection 34:208–213PubMedCrossRef
27.
Zurück zum Zitat Nardone A, de Ory F, Carton M, Cohen D, van Damme P, Davidkin I et al (2007) The comparative sero-epidemiology of varicella zoster virus in 11 countries in the European region. Vaccine 25:7866–7872PubMedCrossRef Nardone A, de Ory F, Carton M, Cohen D, van Damme P, Davidkin I et al (2007) The comparative sero-epidemiology of varicella zoster virus in 11 countries in the European region. Vaccine 25:7866–7872PubMedCrossRef
28.
Zurück zum Zitat Borras E, Domínguez A, Batalla J, Torner N, Cardeñosa N, Nebot M, Plasencia A, Salleras L (2007) Vaccination coverage in indigenous and immigrant children under 3 years of age in Catalonia (Spain). Vaccine 25:3240–3243PubMedCrossRef Borras E, Domínguez A, Batalla J, Torner N, Cardeñosa N, Nebot M, Plasencia A, Salleras L (2007) Vaccination coverage in indigenous and immigrant children under 3 years of age in Catalonia (Spain). Vaccine 25:3240–3243PubMedCrossRef
29.
Zurück zum Zitat Smith WJ, Jackson LA, Watts DH, Koepsell TD (1998) Prevention of chickenpox in reproductive-age women: cost-effectiveness of routine prenatal screening with postpartum vaccination of susceptibles. Obstet Gynecol 92:535–545PubMedCrossRef Smith WJ, Jackson LA, Watts DH, Koepsell TD (1998) Prevention of chickenpox in reproductive-age women: cost-effectiveness of routine prenatal screening with postpartum vaccination of susceptibles. Obstet Gynecol 92:535–545PubMedCrossRef
30.
Zurück zum Zitat Plans- Rubió P (2004) Critical prevalence of antibodies minimizing vaccination costs for hepatitis A, hepatitis B, varicella, measles and tetanus in adults and adolescents in Catalonia (Spain). Vaccine 22:4002–4013PubMedCrossRef Plans- Rubió P (2004) Critical prevalence of antibodies minimizing vaccination costs for hepatitis A, hepatitis B, varicella, measles and tetanus in adults and adolescents in Catalonia (Spain). Vaccine 22:4002–4013PubMedCrossRef
31.
Zurück zum Zitat Plans P, Espuñes J, Plasencia A, Salleras L (2007) Prevalence of varicella-zoster antibodies in pregnant women in Catalonia (Spain). Rationale for varicella vaccination of women childbearing age. Br J Obstet Gynaecol 114:122–127 Plans P, Espuñes J, Plasencia A, Salleras L (2007) Prevalence of varicella-zoster antibodies in pregnant women in Catalonia (Spain). Rationale for varicella vaccination of women childbearing age. Br J Obstet Gynaecol 114:122–127
Metadaten
Titel
Seroprevalence of varicella zoster virus infection in child and adult population of Catalonia (Spain)
verfasst von
Lluís Salleras
Àngela Domínguez
Pere Plans
Josep Costa
Neus Cardeñosa
Núria Torner
Antoni Plasència
Publikationsdatum
01.09.2008
Verlag
Springer-Verlag
Erschienen in
Medical Microbiology and Immunology / Ausgabe 3/2008
Print ISSN: 0300-8584
Elektronische ISSN: 1432-1831
DOI
https://doi.org/10.1007/s00430-007-0064-z

Weitere Artikel der Ausgabe 3/2008

Medical Microbiology and Immunology 3/2008 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.